-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 9.1% in November
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 9.1% in November
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 704,700 shares, a drop of 9.1% from the November 15th total of 775,600 shares. Based on an average trading volume of 1,380,000 shares, the short-interest ratio is presently 0.5 days. Currently, 2.9% of the company's shares are short sold.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on the company. BTIG Research lifted their target price on Acumen Pharmaceuticals from $15.00 to $22.00 and gave the company a "buy" rating in a research report on Wednesday, October 5th. Credit Suisse Group decreased their target price on Acumen Pharmaceuticals from $17.00 to $16.00 and set an "outperform" rating for the company in a research report on Tuesday, November 15th.
Get Acumen Pharmaceuticals alerts:Acumen Pharmaceuticals Trading Up 8.5 %
Shares of NASDAQ:ABOS opened at $5.72 on Monday. Acumen Pharmaceuticals has a 12-month low of $3.02 and a 12-month high of $10.97. The business's fifty day simple moving average is $6.65 and its 200-day simple moving average is $5.89.
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. As a group, equities analysts anticipate that Acumen Pharmaceuticals will post -1.01 earnings per share for the current year.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Deep Track Capital LP increased its holdings in shares of Acumen Pharmaceuticals by 34.5% in the 1st quarter. Deep Track Capital LP now owns 2,599,098 shares of the company's stock valued at $10,162,000 after acquiring an additional 666,058 shares during the period. Fiduciary Group LLC purchased a new position in Acumen Pharmaceuticals during the 1st quarter worth $31,000. New York State Common Retirement Fund grew its stake in Acumen Pharmaceuticals by 337.5% during the 1st quarter. New York State Common Retirement Fund now owns 23,981 shares of the company's stock worth $94,000 after buying an additional 18,500 shares during the last quarter. Pathstone Family Office LLC purchased a new position in Acumen Pharmaceuticals during the 3rd quarter worth $2,540,000. Finally, Point72 Asset Management L.P. purchased a new position in Acumen Pharmaceuticals during the 3rd quarter worth $411,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.
About Acumen Pharmaceuticals
(Get Rating)
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Read More
- Get a free copy of the StockNews.com research report on Acumen Pharmaceuticals (ABOS)
- Is it Time to Take a Bite into Domino's Pizza?
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 704,700 shares, a drop of 9.1% from the November 15th total of 775,600 shares. Based on an average trading volume of 1,380,000 shares, the short-interest ratio is presently 0.5 days. Currently, 2.9% of the company's shares are short sold.
Acumen PharmPharmticals，Inc.(納斯達克代碼：ABOS-GET評級)是空頭股數11月份股價大幅下跌的接受者。截至11月30日，空頭股數共有70.47萬股，較11月15日的77.56萬股下降了9.1%。以138萬股的平均成交量計算，目前短息比為0.5天。目前，該公司2.9%的股票被賣空。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of equities research analysts have weighed in on the company. BTIG Research lifted their target price on Acumen Pharmaceuticals from $15.00 to $22.00 and gave the company a "buy" rating in a research report on Wednesday, October 5th. Credit Suisse Group decreased their target price on Acumen Pharmaceuticals from $17.00 to $16.00 and set an "outperform" rating for the company in a research report on Tuesday, November 15th.
許多股票研究分析師對該公司進行了分析。BTIG Research在10月5日(週三)的一份研究報告中將Acumen PharmPharmticals的目標價從15.00美元上調至22.00美元，並給予該公司“買入”評級。瑞士信貸集團在11月15日週二的研究報告中將Acumen PharmPharmticals的目標價從17.00美元下調至16.00美元，並為該公司設定了“跑贏大盤”的評級.
Acumen Pharmaceuticals Trading Up 8.5 %
Acumen製藥交易上漲8.5%
Shares of NASDAQ:ABOS opened at $5.72 on Monday. Acumen Pharmaceuticals has a 12-month low of $3.02 and a 12-month high of $10.97. The business's fifty day simple moving average is $6.65 and its 200-day simple moving average is $5.89.
週一，新浪納斯達克的股價開盤報5.72美元。Acumen PharmPharmticals的12個月低點為3.02美元，12個月高位為10.97美元。該業務的50日簡單移動均線切入位為6.65美元，200日簡單移動均線切入位為5.89美元。
Institutional Inflows and Outflows
機構資金流入和流出
Institutional investors and hedge funds have recently made changes to their positions in the stock. Deep Track Capital LP increased its holdings in shares of Acumen Pharmaceuticals by 34.5% in the 1st quarter. Deep Track Capital LP now owns 2,599,098 shares of the company's stock valued at $10,162,000 after acquiring an additional 666,058 shares during the period. Fiduciary Group LLC purchased a new position in Acumen Pharmaceuticals during the 1st quarter worth $31,000. New York State Common Retirement Fund grew its stake in Acumen Pharmaceuticals by 337.5% during the 1st quarter. New York State Common Retirement Fund now owns 23,981 shares of the company's stock worth $94,000 after buying an additional 18,500 shares during the last quarter. Pathstone Family Office LLC purchased a new position in Acumen Pharmaceuticals during the 3rd quarter worth $2,540,000. Finally, Point72 Asset Management L.P. purchased a new position in Acumen Pharmaceuticals during the 3rd quarter worth $411,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.
機構投資者和對沖基金最近改變了他們在該股的頭寸。深軌資本有限責任公司第一季度增持Acumen PharmPharmticals股票34.5%。在此期間，Deep Track Capital LP額外收購了666,058股，目前擁有2,599,098股該公司股票，價值10,162,000美元。信託集團LLC在第一季度購買了Acumen製藥公司的一個新頭寸，價值3.1萬美元。紐約州共同退休基金第一季度在Acumen PharmPharmticals的持股增加了337.5%。紐約州共同退休基金現在擁有23,981股該公司股票，價值94,000美元，上個季度又購買了18,500股。帕斯通家族辦公室有限責任公司在第三季度購買了Acumen製藥公司的一個新頭寸，價值2,540,000美元。最後，Point72 Asset Management L.P.在第三季度購買了Acumen PharmPharmticals的一個新頭寸，價值411,000美元。63.33%的股票目前由對沖基金和其他機構投資者持有。
About Acumen Pharmaceuticals
關於Acumen製藥公司
(Get Rating)
(獲取評級)
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Acumen製藥公司是一家臨床階段的生物製藥公司，發現和開發治療阿爾茨海默病的療法。該公司專注於開發一種靶向免疫治療候選藥物ACU193，這是一種人源化單抗，正處於I期臨床階段，用於靶向可溶性澱粉樣β寡聚體。
Read More
閱讀更多內容
- Get a free copy of the StockNews.com research report on Acumen Pharmaceuticals (ABOS)
- Is it Time to Take a Bite into Domino's Pizza?
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- 免費獲取StockNews.com關於Acumen製藥的研究報告(ABOS)
- 是時候去Domino‘s Pizza嘗一口了嗎？
- MarketBeat：回顧一週12/12-12/16
- 哪兩家藍籌科技公司提高了他們的指引？
- 你應該擔心埃隆·馬斯克出售他持有的特斯拉股票嗎？
- 拖拉機庫存能否突破杯柄收購點？
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Acumen PharmPharmticals Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acumen製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧